CardioVascular BioTherapeutics Company Profile

10:13 EST 13th December 2018 | BioPortfolio

CardioVascular BioTherapeutics, Inc. (OTC/BB: CVBT) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide leading cause of death. The Company is developing injectable and topical formulations of its active pharmacological ingredient (API) to facilitate the growth of new blood vessels (angiogenesis) in the heart, tissues and organs that have been compromised by impaired blood supply (hypoxia, ischemia). The Company’s API contains FGF-1141 a human protein manufactured using a proprietary technology. FGF-1 stimulates the growth and proliferation of the three main cell types of blood vessels; endothelial cells, smooth muscles cells and pericytes. CVBT-141A, the Company’s lead drug candidate successfully completed initial clinical trials in Germany during the 1990s, with no drug-related adverse events and a statistically significant increase in localized blood vessel growth (and perfusion) both in patients also receiving coronary by-pass procedures and in patients with severe coronary heat disease (CHD) receiving CVBT-141A, as the sole therapy. Enrollment and treatment has been completed in an FDA authorized Phase I study with CVBT-141A, administered via injection in severe CHD patients. The protocol design for the Phase II trial is underway, with FDA input, and is planned to initiate in 2007. CardioVascular BioTherapeutics, Inc. is committed to conducting additional clinical trials to establish the positive effect of FGF-1141 aimed at improving the quality of life for those suffering from heart disease, stroke, diabetic wounds, or peripheral artery disease, and pledges to continue exploration for additional applications of FGF-1.


1635 Village Center Circle
Suite 250
Las Vegas
United States of America


Phone: (702) 248-1174

News Articles [781 Associated News Articles listed on BioPortfolio]

Executives On The Move: New CEOs At Perrigo And SanBio, CMOs At CardioVascular BioTherapeutics And Harpoon Therapeutics, And A Retirement At BTG

This week's company moves include a new CEO for Perrigo, while Harpoon Therapeutics and CardioVascular BioTherapeutics get new chief medical...   

Asterias Biotherapeutics to merge with BioTime

US-based biotechnology firms BioTime and Asterias Biotherapeutics have entered into a definitive merger agreement to form an integrated company focussed...Read More... The post Asterias Biotherapeutic...

Codexis Appoints Biotherapeutics R&D VP

Dr. Alaoui will be responsible for the biotherapeutics discovery pipeline and acceleration of drug candidates to the clinic

Cancer Research UK launches new research hub for biotherapeutics

Cancer Research UK has launched a global centre of excellence in London to facilitate research on biotherapeutics as a treatment...Read More... The post Cancer Research UK launches new research hub fo...

Pall and Celltheon form strategic biotherapeutics partnership

This partnership will deliver integrated manufacturing solutions for customers developing biotherapeutics

Improving understanding of biotherapeutics and biosimilars

Additional information on biosimilars and biotherapeutics have been published in Europe.

Gene Biotherapeutics sells Excellagen technology platform to Olaregen

Olaregen is a special purpose entity which was formed by an unaffiliated investment group to acquire and commercialize advanced wound healing therapeutics for multiple vertical markets. Gene Biotherap...

BioTime signs merger deal with Asterias Biotherapeutics

The merger of BioTime and Asterias Biotherapeutics will enable to create a major cell therapy company. As per terms of the deal, Asterias stockholders will secure 0.71 common The post BioTime signs m...

Drugs and Medications [17 Associated Drugs and Medications listed on BioPortfolio]


Plasma Protein Fraction (Human) 5%, USPPlasmanate®


Albumin (Human) 5%, USPPlasbumin ®-5


Albumin (Human) 5%, USPPlasbumin ®-5


Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated


Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [1633 Associated PubMed Articles listed on BioPortfolio]

Synthetic Biology and Engineered Live Biotherapeutics: Toward Increasing System Complexity.

Recent advances in synthetic biology and biological system engineering have allowed the design and construction of engineered live biotherapeutics targeting a range of human clinical applications. In ...

Cell Penetration Profiling Using the Chloroalkane Penetration Assay.

Biotherapeutics are a promising class of molecules in drug discovery, but they are often limited to extracellular targets due to their poor cell penetration. High-throughput cell penetration assays ar...

Live bacterial biotherapeutics in the clinic.

Association of Change in Cardiovascular Risk Factors With Incident Cardiovascular Events.

There is consistent evidence of the association between ideal cardiovascular health and lower incident cardiovascular disease (CVD); however, most studies used a single measure of cardiovascular healt...

Cardiovascular Effects of Different GLP-1 Receptor Agonists in Patients with Type 2 Diabetes.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have positive effects on weight loss, blood pressure, hyperlipidemia, and glycemic control. They exhibit a broad range of effects on the cardiovas...

Clinical Trials [2960 Associated Clinical Trials listed on BioPortfolio]

Cardiovascular Disease Cohort in Guangdong Province

Patients with cardiovascular diseases from Guangdong province will be recruited and followed up for at least 4 years to evaluate the risk factors for cardiovascular-related mortality and d...

Factors Influencing Cardiovascular Prognosis

The purpose of this study is to identify risks for cardiovascular events in a follow up period of 10 years.

Work Organization and Cardiovascular Disease

To determine the combined effects of job strain and social isolation on cardiovascular morbidity and mortality.

Role of Vitamin D in Secondary Prevention of Cardiovascular Events

The purpose of this study is to determine if Vitamin D supplementation helps prevent recurrent cardiovascular events, such as heart attack or stroke, in patients who have already experienc...

Partnership Programs for Reducing Cardiovascular Disparities in Native Hawaiians

The purpose of this study is to improve cardiovascular disease (CVD) outcomes in racial and ethnic minorities in Hawaii.

Companies [718 Associated Companies listed on BioPortfolio]

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

CardioVascular BioTherapeutics

CardioVascular BioTherapeutics, Inc. (OTC/BB: CVBT) is a biopharmaceutical company focused on developing protein drug candidates to be used in the treatment of cardiovascular disease, the worldwide le...

Cardiovascular Consultants, Ltd.

Cardiovascular Consultants, Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate ...

Cardiovascular Consultants Ltd.

Cardiovascular Consultants Ltd., founded in 1986 by Dr. Andrei Damian, is dedicated to providing patients in Phoenix and surrounding areas with the most advanced and appropriate c...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

More Information about "CardioVascular BioTherapeutics" on BioPortfolio

We have published hundreds of CardioVascular BioTherapeutics news stories on BioPortfolio along with dozens of CardioVascular BioTherapeutics Clinical Trials and PubMed Articles about CardioVascular BioTherapeutics for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CardioVascular BioTherapeutics Companies in our database. You can also find out about relevant CardioVascular BioTherapeutics Drugs and Medications on this site too.

Quick Search


Relevant Topics

Cardiovascular disease (CVD)
Acute Coronary Syndromes (ACS) Blood Cardiovascular Dialysis Hypertension Stent Stroke Vascular Cardiovascular disease (CVD) includes all the diseases of the heart and circulation including coronary heart disease (angina...

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Corporate Database Quicklinks

Searches Linking to this Company Record